ACC 25 - The API-CAT Study shows reduced-dose apixaban is non-inferior to full-dose apixaban for extended anticoagulation in patients with active cancer who have completed 6 months of anticoagulant therapy for venous thromboembolism (VTE).

Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Prof Isabelle Mahe (Paris Cite University, Paris, FR) to discuss the findings from API-CAT, a randomized, double-blind non-inferiority trial to investigate whether low-dose apixaban (2.5mg twice daily) is non inferior to full-dose apixaban (5mg twice daily) in 1766 patients with active cancer for the prevention of recurrent venous thromboembolism.

The primary outcome was the incidence of ajudicated composite endpoint of recurrent symptomatic VTE, incidental VTE or death due to pulmonary embolism during the treatment period. Findings showed that in patients with active cancer who have completed 6 months of anticoagulant treatment, extended therapy with reduced-dose apixaban was non-inferior to full-dose apixaban in preventing VTE.

Recorded Onsite at ACC 25, Chicago.

Editors: Yazmin Sadik, Jordan Rance

Videographers: Dan Brent, David Ben-Harosh

Support: This is an independent interview produced by Radcliffe Cardiology.